TMCnet News
Takeda Pharmaceuticals Marks its 240th Founding AnniversaryDUBAI, UAE, June 16, 2021 /PRNewswire/ -- Takeda Pharmaceuticals Company (TSE: 4502) (NYSE: TAK) ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, headquartered in Japan, is celebrating its 240th founding anniversary in June 2021, marking a significant milestone in bringing Better Health and a Brighter Future to people worldwide.
The company was first founded by Chobei Takeda in 1781 in Osaka, Japan, with the Pharmaceutical Manufacturing Business starting in 1895 and the Takeda Pharmaceutical Company established in 1915. Today the company has a global presence in over 80 countries with 80 manufacturing and three research sites. Takeda's R&D efforts are currently focused on four therapeutic areas: oncology, rare diseases, neuroscience, and gastroenterology, with targeted R&D investments in plasma-derived therapies and vaccines. Dr. Mahender Nayak, Area Head, ICMEA (India, C.I.S., Middle East, Turkey, and Africa) said, "With roots as a family-startup, our incredible legacy is anchored by our values, and guided by a strong commitment to the highest ethical standards. Our growth will continue to be driven by decisions and actions based on Patient-Trust Reputation-Business, in that order. At both global and area levels, we will continue to deliver sustainable, profitable growth through ensuring patient access to our innovative treatments. As we begin our 240th year, Takeda seeks to deliver even greater value for our patients, people and the planet." He added, "Our focus here across ICMEA is on our innovative portfolio that will see multiple launches planned in 2021 and beyond. Through strategic partnerships, we aim to increase the number of patient lives positively impacted by various initiatives such as Takeda's global Access to Medicines initiatives. Among recent examples is our work in supporting controlling mass disease outbreaks. Studies[1] suggest that our dengue vaccine candidate could help with outbreak prevention, reducing rates of hospitalization and protecting people from dengue regardless of their previous exposure throughout three years." Takeda-ism incorporates Integrity, Fairness, Honesty and Perseverance, with Integrity at the core. Takeda aims to achieve a revenue goal of JPY 1 trillion[2] by FY2030 for its Growth and Emerging Markets Business Unit which includes ICMEA in its remit. Takeda has also achieved carbon neutrality[3] in its value chain in FY 2019, delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets, including more than 30 renewable energy and carbon offset projects across 12 countries. Takeda's ICMEA headquarters in Dubai have received silver level LEED certification. Globally, the company has almost 50,000 employees. The ICMEA Area comprises 38 countries with around 1,000 employees. The region has a gender mix of 58 percent women and 42 percent women with more than 54 nationalities. Takeda was named global Top Employer[4] for fourth consecutive year. About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com. Important Notice For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. [3] takeda.com/newsroom/newsreleases/2021/takeda-achieved-carbon-neutrality-in-2020/ Logo - https://mma.prnewswire.com/media/1534807/Takeda_Logo.jpg
SOURCE Takeda Pharmaceuticals 
|
View original content to download multimedia: